Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Everest Medical

This article was originally published in The Gray Sheet

Executive Summary

Everest Medical: Firm plans to introduce the BiSECTOR 5 mm bipolar ligating forceps for use in coagulation of vessels during electrosurgery and to transect vessel tributaries prior to saphenous vein harvesting at the Jan. 23-25 Association of Physician Assistants in Cardiovascular Surgery meeting and the Society of Thoracic Surgery conference Jan. 26-28, both of which are being held in New Orleans. The company also is debuting an Everest-branded version of its bipolar scissors. Everest will market the instruments "for use with non-Guidant saphenous vein harvesting approaches and systems," the company says in a Jan. 20 release. The company entered a supply agreement with Guidant in June 1997 to market Everest instruments with Guidant's minimally invasive saphenous vein harvesting system...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel